These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36473763)

  • 21. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
    Schumann J; Henrich EC; Strobl H; Prondzinsky R; Weiche S; Thiele H; Werdan K; Frantz S; Unverzagt S
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009669. PubMed ID: 29376560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
    Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
    Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease.
    Burkhardt BE; Rücker G; Stiller B
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD009515. PubMed ID: 25806562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children].
    Prijić S; Rakić S; Nikolić L; Jovicić B; Stajević M; Vukomanović V; Kosutić J
    Vojnosanit Pregl; 2011 Nov; 68(11):979-84. PubMed ID: 22191317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials.
    Belletti A; Benedetto U; Biondi-Zoccai G; Leggieri C; Silvani P; Angelini GD; Zangrillo A; Landoni G
    J Crit Care; 2017 Feb; 37():91-98. PubMed ID: 27660923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inotropic support during experimental endotoxemic shock: part II. A comparison of levosimendan with dobutamine.
    Cunha-Goncalves D; Perez-de-Sa V; Larsson A; Thörne J; Blomquist S
    Anesth Analg; 2009 Nov; 109(5):1576-83. PubMed ID: 19713252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Randomized Blinded Study of the Left Ventricular Myocardial Performance Index Comparing Epinephrine to Levosimendan following Cardiopulmonary Bypass.
    Salgado Filho MF; Barral M; Barrucand L; Cavalcanti IL; Verçosa N
    PLoS One; 2015; 10(12):e0143315. PubMed ID: 26655803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study.
    Shah B; Sharma P; Brahmbhatt A; Shah R; Rathod B; Shastri N; Patel J; Malhotra A
    Indian J Pharmacol; 2014; 46(1):29-34. PubMed ID: 24550581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levosimendan is superior to dobutamine as an inodilator in the treatment of pulmonary hypertension for children undergoing cardiac surgery.
    Ebade AA; Khalil MA; Mohamed AK
    J Anesth; 2013 Jun; 27(3):334-9. PubMed ID: 23223915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study.
    Morelli A; Donati A; Ertmer C; Rehberg S; Lange M; Orecchioni A; Cecchini V; Landoni G; Pelaia P; Pietropaoli P; Van Aken H; Teboul JL; Ince C; Westphal M
    Crit Care; 2010; 14(6):R232. PubMed ID: 21182783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial.
    Orme RM; Perkins GD; McAuley DF; Liu KD; Mason AJ; Morelli A; Singer M; Ashby D; Gordon AC
    Trials; 2014 Jun; 15():199. PubMed ID: 24894386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levosimendan improves postresuscitation outcomes in a rat model of CPR.
    Huang L; Weil MH; Sun S; Cammarata G; Cao L; Tang W
    J Lab Clin Med; 2005 Nov; 146(5):256-61. PubMed ID: 16242524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.
    Huang X; Lei S; Zhu MF; Jiang RL; Huang LQ; Xia GL; Zhi YH
    J Zhejiang Univ Sci B; 2013 May; 14(5):400-15. PubMed ID: 23645177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
    Bergh CH; Andersson B; Dahlström U; Forfang K; Kivikko M; Sarapohja T; Ullman B; Wikström G
    Eur J Heart Fail; 2010 Apr; 12(4):404-10. PubMed ID: 20335355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery].
    Alvarez J; Bouzada M; Fernández AL; Caruezo V; Taboada M; Rodríguez J; Ginesta V; Rubio J; García-Bengoechea JB; González-Juanatey JR
    Rev Esp Cardiol; 2006 Apr; 59(4):338-45. PubMed ID: 16709386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone.
    Barraud D; Faivre V; Damy T; Welschbillig S; Gayat E; Heymes C; Payen D; Shah AM; Mebazaa A
    Crit Care Med; 2007 May; 35(5):1376-82. PubMed ID: 17414729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE.
    Mebazaa A; Nieminen MS; Filippatos GS; Cleland JG; Salon JE; Thakkar R; Padley RJ; Huang B; Cohen-Solal A
    Eur J Heart Fail; 2009 Mar; 11(3):304-11. PubMed ID: 19158152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy and safety of intravenous levosimendan compared with dobutamine in decompensated heart failure].
    Wang L; Cui L; Wei JP; Li GP; Qi GX; Hao YM; Wang WZ; Li HM; Liu J; Jiang DJ; Zhang YD
    Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Jun; 38(6):527-30. PubMed ID: 21033135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of levosimendan on E/E' ratio in patients with ischemic heart failure.
    Duygu H; Ozerkan F; Nalbantgil S; Zoghi M; Akilli A; Akin M; Nazli C; Ergene O
    Int J Cardiol; 2008 Jan; 123(2):201-3. PubMed ID: 17316845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.